[Localized lipohypertrophy during growth hormone therapy].
Accumulation of subcutaneous fat is described in a 51-year-old woman with panhypopituitarism treated on all insufficient pituitary axes, including growth hormone (GH). Malnutrition and alcoholic liver disease caused reduced synthesis of hepatic insulin-like growth factor I (IGF-I), and the function of IGF-I as biochemical marker of the GH effect was compromised. Peripheral levels of GH and IGF-I in tissues may have reached supra physiological levels and induced localised lipohypertrophy. Adjustment of GH treatment should not rest in all cases on IGF-I alone, but also depend on the clinical effect. Adjustment should follow suspected adverse events, such as lipohypertrophy, which is, however, an unusual complication of GH therapy.
Mersebach
Henriette
H
Medicinsk endokrinologisk klinik PE-2131, H:S Rigshospitalet, DK-2100 København ø.
Feldt-Rasmussen
Ulla F
UF
D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006984:Hypertrophy / Q000139:chemically induced* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008060:Lipodystrophy / Q000139:chemically induced* / Q000378:metabolism; D008875:Middle Aged
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone